This company has been acquired
Agile Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Agile Therapeutics has a total shareholder equity of $-21.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.0M and $36.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.85m |
| Equity | -US$21.91m |
| Total liabilities | US$36.88m |
| Total assets | US$14.96m |
Recent financial health updates
Recent updates
Agile appoints chief commercial officer from within ranks amid leadership revamp
Oct 10Agile gains as H.C. Wainwright sees 630% upside potential
Jul 11Agile Therapeutics prices $24M upsized stock offering
Jul 01Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy
Apr 04Agile Therapeutics: Bullish On Capitulation And Max Pain
Oct 19Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy
Jul 30Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 06How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?
Feb 25
Agile Therapeutics issues cash projection at JP Morgan healthcare conference
Jan 14Assessing Agile Therapeutics
Jan 10How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?
Jan 04Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch
Nov 30Agile Therapeutics EPS in-line
Nov 12Financial Position Analysis
Short Term Liabilities: AGRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AGRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AGRX is debt free.
Reducing Debt: AGRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AGRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2.1% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/26 16:03 |
| End of Day Share Price | 2024/08/26 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Agile Therapeutics, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chiara Russo | Cantor Fitzgerald & Co. |
| Colin Scarola | CFRA Equity Research |
| Edward White | FBR Capital Markets & Co. |